Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medicamen BiotechBOM:531146 +5.37%64 5-Year Yield-on-Cost % is 0.51 as of Sep. 15, 2026, which is 70% above its 10-year median of 0.30. GuruFocus rates BOM:531146 with a GF Score™ of 64/100 and a GF Value™ of ₹489.87 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 507 Drug Manufacturers companies, Medicamen Biotech ranks worse than 83.43% on this metric.
Medicamen Biotech's yield on cost for the quarter that ended in Jun. 2026 was 0.51.
The historical rank and industry rank for Medicamen Biotech's 5-Year Yield-on-Cost % or its related term are showing as below:
BOM:531146'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.11 Med: 0.3 Max: 0.9
Current: 0.51
During the past 13 years, Medicamen Biotech's highest Yield on Cost was 0.90. The lowest was 0.11. And the median was 0.30.
BOM:531146's 5-Year Yield-on-Cost % is ranked worse than 83.43% of 507
companies
in the Drug Manufacturers industry
Industry Median: 2.41
vs BOM:531146: 0.51
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Medicamen Biotech 5-Year Yield-on-Cost % Related Terms
BOM:531146 vs ZTS: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Medicamen Biotech's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medicamen Biotech 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medicamen Biotech's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Medicamen Biotech's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Medicamen Biotech (BOM:531146) has a 5-Year Yield-on-Cost % of 0.51 as of Sep. 15, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Medicamen Biotech and its competitors. This is 70% above median its historical median of 0.30. Over the past decade, Medicamen Biotech's 5-Year Yield-on-Cost % has ranged from 0.11 to 0.90. According to the industry distribution chart, Medicamen Biotech ranks #423 out of 507 companies in the Drug Manufacturers industry, placing it in the top 83.4%.
Is Medicamen Biotech's 5-Year Yield-on-Cost % too high?
Medicamen Biotech's current 5-Year Yield-on-Cost % of 0.51 is 70% above median its 10-year median of 0.30. Over the past 10 years, this metric has ranged from a low of 0.11 to a high of 0.90. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.41. Medicamen Biotech's value of 0.51 is 78.8% below this industry median. Based on the distribution chart, Medicamen Biotech ranks #423 out of 507 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Medicamen Biotech has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medicamen Biotech's 5-Year Yield-on-Cost % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Medicamen Biotech ranks #423 out of 507 companies for 5-Year Yield-on-Cost %. This places Medicamen Biotech in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.41. Medicamen Biotech's value of 0.51 is 78.8% below this benchmark. Historically, Medicamen Biotech's own 5-Year Yield-on-Cost % has ranged from 0.11 to 0.90 over the past decade. While the company's 10-year median is 0.30 vs. the industry median of 2.41, Medicamen Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.41, based on 507 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medicamen Biotech's current 5-Year Yield-on-Cost % of 0.51 is 78.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Medicamen Biotech and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medicamen Biotech's current 5-Year Yield-on-Cost % is 0.51, which is 70% above median its own 10-year median of 0.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicamen Biotech stock overvalued right now?
Based on GuruFocus' analysis, Medicamen Biotech (BOM:531146) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹489.87, compared to a current price of ₹323.50 — trading 34% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.51, which is 70% above median its 10-year median of 0.30 and 78.8% below the Drug Manufacturers industry median of 2.41. Medicamen Biotech's overall GF Score™ is 64/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Medicamen Biotech (BOM:531146), the current 5-Year Yield-on-Cost % is 0.51 as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medicamen Biotech (BOM:531146) Overvalued in 2026?
Based on GuruFocus' analysis, Medicamen Biotech stock appears to be undervalued.
The current stock price of ₹323.50 is trading 34% below its estimated GF Value™ of ₹489.87.
GuruFocus considers Medicamen Biotech to be Significantly Undervalued.
Key valuation signals for BOM:531146:
5-Year Yield-on-Cost %: 0.51 (70% above median its 10-year median of 0.30)
GF Value™: ₹489.87 vs. price of ₹323.50 (34% below fair value)
Industry Position: 78.8% below the Drug Manufacturers median (#423 of 507)
No single metric tells the full story. See the BOM:531146 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medicamen Biotech Ltd is an Indian based pharmaceutical company. The company is engaged in developing and manufacturing Pharmaceuticals formulations products. It manufactures Tablets, Capsules, Oral liquids, Dry syrups, Ointments, and Oral rehydration solution. It generates revenue from the sale of pharmaceutical products.
64GF Score
Get the complete analysis for BOM:531146
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:531146 has been successfully added to your 
